berotralstat
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Biocryst's portfolio. Mechanism: Plasma kallikrein inhibitor.
- Mechanism
- Plasma kallikrein inhibitor
pharma · Hereditary Angioedema · Influenza · BCRX
Biocryst
Biocryst drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
München, DE HQ
1986 Founded
6 Employees
Public company Type
BCRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- München, DE
- Founded
- 1986
- Employees
- 6
- Programs
- 37
- Drugs
- 17
- Patents
- 72
Biocryst pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Biocryst drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Plasma kallikrein.
- Target
- Plasma kallikrein
- Mechanism
- Plasma kallikrein inhibitor
-
Development asset linked to Biocryst in public FDA and regional records.
-
Development asset linked to Biocryst in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Biocryst in public FDA and regional records.
-
colchicine
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Biocryst's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
eculizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor
-
Development asset linked to Biocryst in public FDA and regional records. Molecular target: Purine nucleoside phosphorylase.
- Target
- Purine nucleoside phosphorylase
- Mechanism
- Purine nucleoside phosphorylase inhibitor
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Biocryst's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Biocryst's portfolio.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
peramivir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Neuraminidase.
- Target
- Neuraminidase
- Mechanism
- Neuraminidase inhibitor
-
Development asset linked to Biocryst in public FDA and regional records.
-
Development asset linked to Biocryst in public FDA and regional records.
-
Development asset linked to Biocryst in public FDA and regional records.